Selcia, NeuroVive sign R&D pact to develop mitochondrial medicines
Under the agreement, both the parties have invested for combining Selcia’s medicinal and analytical chemistry, with NeuroVive’s research and development programs in mitochondrial medicine. NeuroVive CEO Mikael Bronnegard
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.